These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18676865)

  • 1. Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer.
    Liu Y; Mo JQ; Hu Q; Boivin G; Levin L; Lu S; Yang D; Dong Z; Lu S
    Cancer Res; 2008 Aug; 68(15):6396-406. PubMed ID: 18676865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.
    Nomura T; Yamasaki M; Hirai K; Inoue T; Sato R; Matsuura K; Moriyama M; Sato F; Mimata H
    Mol Cancer; 2013 Apr; 12():27. PubMed ID: 23566222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer.
    Dong Z; Liu Y; Lu S; Wang A; Lee K; Wang LH; Revelo M; Lu S
    Mol Endocrinol; 2006 Oct; 20(10):2315-25. PubMed ID: 16762975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Vav3 oncogene enhances the malignant potential of prostate cancer cells under chronic hypoxia.
    Hirai K; Nomura T; Yamasaki M; Inoue T; Narimatsu T; Chisato Nakada PD; Yoshiyuki Tsukamoto PD; Matsuura K; Sato F; Moriyama M; Mimata H
    Urol Oncol; 2014 Feb; 32(2):101-9. PubMed ID: 23403204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer.
    Lee K; Liu Y; Mo JQ; Zhang J; Dong Z; Lu S
    BMC Cancer; 2008 Jun; 8():158. PubMed ID: 18518979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer.
    Dong Z; Liu Y; Levin L; Oleksowicz L; Wang J; Lu S
    Oncol Rep; 2011 Jun; 25(6):1511-6. PubMed ID: 21455584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.
    Lyons LS; Rao S; Balkan W; Faysal J; Maiorino CA; Burnstein KL
    Mol Endocrinol; 2008 Mar; 22(3):597-608. PubMed ID: 18079321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular mechanism of Vav3 oncogene on upregulation of androgen receptor activity in prostate cancer cells.
    Liu Y; Wu X; Dong Z; Lu S
    Int J Oncol; 2010 Mar; 36(3):623-33. PubMed ID: 20126983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
    Lyons LS; Burnstein KL
    Mol Endocrinol; 2006 May; 20(5):1061-72. PubMed ID: 16384856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer.
    Rao S; Lyons LS; Fahrenholtz CD; Wu F; Farooq A; Balkan W; Burnstein KL
    Oncogene; 2012 Feb; 31(6):716-27. PubMed ID: 21765461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crosstalking between androgen and PI3K/AKT signaling pathways in prostate cancer cells.
    Lee SH; Johnson D; Luong R; Sun Z
    J Biol Chem; 2015 Jan; 290(5):2759-68. PubMed ID: 25527506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth.
    Wu F; Peacock SO; Rao S; Lemmon SK; Burnstein KL
    J Biol Chem; 2013 Feb; 288(8):5463-74. PubMed ID: 23281476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence.
    Lin KT; Gong J; Li CF; Jang TH; Chen WL; Chen HJ; Wang LH
    Cancer Res; 2012 Jun; 72(12):3000-9. PubMed ID: 22659453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model.
    Shukla S; Maclennan GT; Marengo SR; Resnick MI; Gupta S
    Prostate; 2005 Aug; 64(3):224-39. PubMed ID: 15712212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.
    Dong Z; Liu Y; Scott KF; Levin L; Gaitonde K; Bracken RB; Burke B; Zhai QJ; Wang J; Oleksowicz L; Lu S
    Carcinogenesis; 2010 Nov; 31(11):1948-55. PubMed ID: 20837598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation.
    Zeng L; Sachdev P; Yan L; Chan JL; Trenkle T; McClelland M; Welsh J; Wang LH
    Mol Cell Biol; 2000 Dec; 20(24):9212-24. PubMed ID: 11094073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Vav3 could reverse the drug resistance of gastric cancer cells by downregulating JNK signaling pathway.
    Tan B; Li Y; Zhao Q; Fan L; Liu Y; Wang D; Zhao X
    Cancer Gene Ther; 2014 Dec; 21(12):526-31. PubMed ID: 25430880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
    Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
    Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Association between polymorphism in Vav3 genes and risk of primary prostatic cancer in Chinese Han population].
    Liu M; Miao N; Zhu Y; Gu CY; Shi XL; Cui WL; Zhang W; Li QX
    Zhonghua Bing Li Xue Za Zhi; 2016 Jul; 45(7):451-6. PubMed ID: 27430689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate.
    Renner O; Fominaya J; Alonso S; Blanco-Aparicio C; Leal JF; Carnero A
    Carcinogenesis; 2007 Jul; 28(7):1418-25. PubMed ID: 17372272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.